Sleep Apnea Syndrome and Vitamin D

• Status: Unknown status
• Trial end date: 2012-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a highly prevalent disorder with multiple comorbidities.

OSAHS is characterized by repetitive episodes of airflow reduction (hypopnoea) or cessation (apnoea) due to upper airway collapse during sleep. Its major risk factor is obesity. However, its pathogenesis is complex and multifactorial. Reduced upper airway muscle tonus and/or unstable neuromuscular output seem to be involved in this collapsus.

A normal vitamin D status is necessary for normal muscle function and neuromuscular output. As obesity is associated with a high rate of hypovitaminosis D, it appears of interest to evaluate the effect of vitamin D supplementation on OSAHS patients with vitamin D deficiency.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Collaborators: Centre de Recherche en Nutrition Humaine d'Auvergne; Centre de Recherche en Nutrition Humaine Rhone-Alpe; Laboratoire Cidelec; Laboratoire Crinex
• Treatments: Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• Moderate to severe obstructive sleep apnoea (AHI > 15)

• With or without continuous positive airway pressure for a minimum of six months

• aged 30-75 years

• Vitamin D2D3 level < 30 ng/ml

Exclusion Criteria:

• Diseases or therapy known to interfere with phospho-calcium or vitamin D metabolism

• Patients with mixed sleep apnoea (central and obstructive)

• Patients with CPAP use < 4 hours per night

• Patients with maxillofacial or oro-pharyngeal diseases)

• Patients with chronic respiratory failure, hypercapnic patients

• Muscle diseases

• Alcohol intake > 2 glasses per day

• Body mass index > 40 kg/m2